CERS6 and metabolic dysfunction-associated steatotic liver disease: Increased expression of CerS6, an enzyme involved in de novo ceramide synthesis, is known to contribute to MASLD development [33,38], while Cers6 ablation has recently been shown to inhibit ALD (alcohol-associated liver disease) progression by improving glucose homeostasis [39].